Developer docs
API playgroundTry for free, no card

Search company profiles

NextMed

Full company profile

uuid0003x9n

Namestring
NextMed
Legal namestring
NextMed, LLC
Websiteurl
nextmed.net
Company typeenum
Private
Founded yearint
1996
Descriptiontext

NextMed, LLC is a privately held, founder-owned urology services company founded in 1996 in Tucson, Arizona, that operates the largest US mobile lithotripsy platform serving more than 400 medical facilities and 1,000 urologists nationwide. Its core business is providing mobile Extracorporeal Shock Wave Lithotripsy (ESWL) units, trained technologists, and data-driven treatment protocols to physician offices and hospitals, enabling partners to offer non-invasive kidney stone treatment without owning equipment or maintaining specialized staff. The company extends this platform through NextWave (in-office ESWL delivered inside the urologist's own office), URS+ (ureteroscopy services including capital equipment, consumables, and technicians), and the AI Smart Litho technology suite, which encompasses the Stone Decision Engine (a predictive treatment recommendation algorithm), the International Stone Registry (a proprietary outcomes database of 200,000+ patients and 1,000+ urologists), the Hamilton, Gerber ESWL Training Simulator, and TAS Analytics for technologist performance monitoring.

NextMed generates revenue primarily through managed-service partnerships with physicians and facilities, with custom negotiated, multi-year contracts and a parallel direct-to-consumer channel via the Physician Finder tool. The company supplements its service revenue with a physician-partnership investment model in which urologists take equity positions; one disclosed example cites a $50,000 investment 15+ years ago generating a seven-figure return. Go-to-market is sales-led, executed through business developers who engage urologists and facilities directly, supported by a website, social media, patient education content, and product-led growth through the Stone Decision Engine app. The company holds the only HFAP Comprehensive Lithotripsy Program certification in the United States and the only ACHC comprehensive lithotripsy certification among urology service providers, both of which it helped develop alongside The Joint Commission, and self-reports industry-leading outcomes including an 86.3% ESWL success rate, 4.5% complication rate (vs. 8.4% industry standard), and over 99% patient success rate.

The business is bootstrapped and founder-operated by the Gleason family with no disclosed institutional investors, parent company, or material external funding (a single $170K raise in April 2022 is the only capital event on record). It has continuously operated for 24+ years and is structured as an Arizona LLC headquartered at 6339 E Speedway Blvd, Tucson. Headcount sits in the 101–250 range, and the company's website displays a 2020 copyright notice, indicating source material was captured around that period, which constrains visibility into more recent developments.

Short descriptiontext

NextMed operates the largest US mobile lithotripsy platform, providing AI-enhanced ESWL kidney stone treatment services, trained technologists, and decision-support tools to more than 1,000 urologists and 400 medical facilities nationwide, with sub-brands NextWave (in-office treatment) and URS+ (ureteroscopy services).

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersTucson, United States
HQ citystring
Tucson
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
mobile lithotripsy services, kidney stone treatment, ESWL procedures, urology practice support, AI treatment algorithms
Industry3 codes
PRIMARYHLAHAKAI
Kidney Stone Management & Lithotripsy Devices
SECONDARYHLACAGAA
Diagnostic & Triage Decision Support
Healthcare & Life Sciences/Digital Health & Health IT/Clinical Decision Support (CDS) & Care Pathway Tools
SECONDARYHLAKAOAF
Endourology & Minimally Invasive Urologic Surgery
NAICS code1 code
  • Ambulatory Health Care Services621
SIC code2 codes
  • Electromedical & Electrotherapeutic Apparatus3845
  • Services-Health Services8000
Product category
Urology Services
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model3 records
1Lithotripsy Services
TypeManaged Services
Description

NextMed provides mobile lithotripsy services to urologists and medical facilities. The company operates mobile lithotripsy units that travel to partner facilities, providing non-invasive kidney stone treatment (ESWL). Physicians and facilities partner with NextMed to access state-of-the-art lithotripsy technology, highly trained technologists, and data-driven treatment protocols. The company was founded on principles of transparent financial operations.

nextmed.net
2NextWave In-Office Treatment Services
TypeManaged Services
Description

NextWave brings kidney stone treatment directly to physician offices, providing in-office ESWL treatment with a focused treatment team. This service generates revenue by enabling physicians to perform lithotripsy in their own facilities with NextMed's equipment, technology, and technologist support.

nextmed.net
3Physician Partnership Investments
TypeLicensing Royalties
Description

Physicians invest in NextMed partnerships, with testimonials indicating significant returns. One physician noted a $50,000 total investment 15+ years ago netting a seven-figure return. This suggests a model where physicians become equity partners or investors in the lithotripsy business.

nextmed.net
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure
Pricing details2 tiers
1Custom partnership pricing based on physician and facility needs
ModelOtherBilling cadenceMulti-year contract
Notes

NextMed operates on a partnership model with physicians and facilities. Pricing is negotiated individually through business development conversations. No public pricing tiers are disclosed.

nextmed.net
2Quote-based pricing for lithotripsy services
ModelOtherBilling cadenceMulti-year contract
Notes

Physicians interested in partnering complete contact forms and business developers reach out to discuss pricing. Testimonials suggest investment-based partnership models with returns.

nextmed.net
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 3 records shown
1NextWave
Description

In-office kidney stone treatment service bringing ESWL treatment directly to physician offices, providing convenient in-office treatment options for patients.

nextmed.net
+2 more records
Core offering1 text field

NextMed provides mobile Extracorporeal Shock Wave Lithotripsy (ESWL) services to urologists and medical facilities across the United States, bringing lithotripsy equipment, AI-powered treatment protocols, and trained technologists directly to partner sites. The company also offers the NextWave in-office treatment service for physicians and the URS+ ureteroscopy program, all supported by the proprietary AI Smart Litho technology platform including the Stone Decision Engine and International Stone Registry.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 10 values shown
  • 86.3% ESWL Treatment Success Rate in the last year with Stone Free Rate of 66.3%
+9 more records
Product overview1 text field

NextMed operates as a comprehensive urology services company offering a platform of lithotripsy and urological treatment services. The core offering consists of mobile lithotripsy services using ESWL technology, supplemented by the NextWave in-office treatment sub-brand and the URS+ ureteroscopy service. Central to their differentiation is the AI Smart Litho technology platform, which includes the Stone Decision Engine (predictive treatment recommendation tool), International Stone Registry (clinical outcomes database), and Hamilton, Gerber Training Simulator (physician training tool). NextMed delivers treatment through partnered physicians and facilities nationwide, serving over 400 facilities and 1,000 physicians with demonstrated outcomes including 99% patient success rate and 86.3% ESWL treatment success rate.

Product and service7 records
1Mobile Lithotripsy Service
CategoryMobile healthcare services
Description

NextMed's core mobile lithotripsy service that deploys ESWL equipment and trained technologists to partner urology practices, hospitals, and medical facilities across the United States. Provides non-invasive kidney stone treatment on-site without requiring facilities to invest in lithotripsy equipment.

2NextWave In-Office Treatment
CategoryUrology service sub-brand
Description

Sub-brand service that brings ESWL kidney stone treatment to the physician's office, allowing patients to receive treatment in their urologist's office rather than a hospital. Includes NextMed equipment, technologists, and focused treatment team support.

3URS+ Ureteroscopy Service
CategoryUrology service sub-brand
Description

Comprehensive ureteroscopy service for urologists and medical facilities providing capital equipment, full suite of consumables, expert technicians, and flexible care settings to address labor shortages and capital equipment needs.

4AI Smart Litho Technology Platform
CategoryAI healthcare technology
Description

NextMed's proprietary AI technology platform integrating predictive algorithms, the Stone Decision Engine, the International Stone Registry, and the ESWL Training Simulator to optimize kidney stone treatment selection and delivery.

5Stone Decision Engine (SDE)
CategoryClinical decision support tool
Description

Standalone predictive tool for patients and physicians that determines the best kidney stone treatment options and predicts success and complication rates based on stone characteristics, patient demographics, and anesthesia preferences.

6International Stone Registry (ISR)
CategoryClinical outcomes registry
Description

Clinical outcomes registry aggregating treatment and outcomes data from over 200,000 patients and 1,000 treating urologists, powered by cloud computing and advanced analytical tools to support treatment decisions.

7Hamilton, Gerber ESWL Training Simulator
CategoryMedical training tool
Description

ESWL training simulator for physicians that uses scientific data and patient-specific information to teach optimal shock protocol delivery for Extracorporeal Shock Wave Lithotripsy procedures.

Scale indicator20 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Global leader in endoscopy and urology visualization systems. Karl Storz is a broad incumbent in urology whose ureteroscopy and endoscopy equipment overlaps with NextMed's URS+ ureteroscopy service line and broader urology practice economics.

TypeDirect peer
Description

Swiss manufacturer of shock wave lithotripsy and focused ultrasound devices. Storz Medical supplies ESWL equipment that competes with NextMed's mobile lithotripsy service offering and is a likely technology partner or competitor for any hospital considering insourcing.

TypeBroad incumbent
Description

Diversified medical device giant with a meaningful urology business (acquired through Covidien and other deals). Medtronic competes broadly in urology and is a potential alternative vendor for hospitals weighing mobile lithotripsy outsourcing versus in-house capital investment.

4Cook Medical
TypeBroad incumbent
Description

Privately held medical device manufacturer with a substantial urology portfolio including ureteral stents, stone baskets, and ureteroscopy accessories. Cook Medical overlaps with NextMed's URS+ ureteroscopy consumables offering and broader urology supply chain.

TypeBroad incumbent
Description

Diversified women's health and surgical company with adjacent urology and surgical service exposure. Hologic is a broad incumbent whose hospital relationships and surgical service infrastructure overlap with NextMed's facility-partnership go-to-market.

TypeDirect peer
Description

A leading global manufacturer of lithotripsy devices and ESWL systems. Dornier competes directly with NextMed in the kidney stone management equipment market that NextMed services, particularly for hospitals evaluating whether to outsource mobile lithotripsy or purchase equipment.

TypeBroad incumbent
Description

Medical technology company with a urology portfolio including ureteral access sheaths, stone baskets, and stents. Teleflex is an incumbent supplier whose products overlap with NextMed's URS+ consumables offering and broader urology procedure economics.

TypeBroad incumbent
Description

Large diversified medical device company with a significant urology franchise (including lithotripsy, ureteroscopy, and stone management products). Boston Scientific competes across multiple of NextMed's service lines as a broader incumbent.

TypeBroad incumbent
Description

German medical technology company specializing in urology, endoscopy, and lithotripsy solutions. Richard Wolf is a broad incumbent whose equipment and consumables portfolio competes across NextMed's mobile lithotripsy and ureteroscopy service lines.

TypeBroad incumbent
Description

Global leader in endoscopy with strong urology exposure including flexible ureteroscopes and stone management devices. Olympus competes as an incumbent equipment vendor for hospitals and ASCs evaluating lithotripsy and ureteroscopy capabilities.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability5 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

NextMed

Urology Servicesnextmed.net

NextMed operates the largest US mobile lithotripsy platform, providing AI-enhanced ESWL kidney stone treatment services, trained technologists, and decision-support tools to more than 1,000 urologists and 400 medical facilities nationwide, with sub-brands NextWave (in-office treatment) and URS+ (ureteroscopy services).

What NextMed does

NextMed, LLC is a privately held, founder-owned urology services company founded in 1996 in Tucson, Arizona, that operates the largest US mobile lithotripsy platform serving more than 400 medical facilities and 1,000 urologists nationwide. Its core business is providing mobile Extracorporeal Shock Wave Lithotripsy (ESWL) units, trained technologists, and data-driven treatment protocols to physician offices and hospitals, enabling partners to offer non-invasive kidney stone treatment without owning equipment or maintaining specialized staff. The company extends this platform through NextWave (in-office ESWL delivered inside the urologist's own office), URS+ (ureteroscopy services including capital equipment, consumables, and technicians), and the AI Smart Litho technology suite, which encompasses the Stone Decision Engine (a predictive treatment recommendation algorithm), the International Stone Registry (a proprietary outcomes database of 200,000+ patients and 1,000+ urologists), the Hamilton, Gerber ESWL Training Simulator, and TAS Analytics for technologist performance monitoring.

NextMed generates revenue primarily through managed-service partnerships with physicians and facilities, with custom negotiated, multi-year contracts and a parallel direct-to-consumer channel via the Physician Finder tool. The company supplements its service revenue with a physician-partnership investment model in which urologists take equity positions; one disclosed example cites a $50,000 investment 15+ years ago generating a seven-figure return. Go-to-market is sales-led, executed through business developers who engage urologists and facilities directly, supported by a website, social media, patient education content, and product-led growth through the Stone Decision Engine app. The company holds the only HFAP Comprehensive Lithotripsy Program certification in the United States and the only ACHC comprehensive lithotripsy certification among urology service providers, both of which it helped develop alongside The Joint Commission, and self-reports industry-leading outcomes including an 86.3% ESWL success rate, 4.5% complication rate (vs. 8.4% industry standard), and over 99% patient success rate.

The business is bootstrapped and founder-operated by the Gleason family with no disclosed institutional investors, parent company, or material external funding (a single $170K raise in April 2022 is the only capital event on record). It has continuously operated for 24+ years and is structured as an Arizona LLC headquartered at 6339 E Speedway Blvd, Tucson. Headcount sits in the 101–250 range, and the company's website displays a 2020 copyright notice, indicating source material was captured around that period, which constrains visibility into more recent developments.

NextMed firmographics

Firmographics
Name
NextMed
Legal name
NextMed, LLC
Website
https://nextmed.net
Company type
Private
Founded year
1996
Operating status
Operating
Headcount range
101–250 employees
Short description
NextMed operates the largest US mobile lithotripsy platform, providing AI-enhanced ESWL kidney stone treatment services, trained technologists, and decision-support tools to more than 1,000 urologists and 400 medical facilities nationwide, with sub-brands NextWave (in-office treatment) and URS+ (ureteroscopy services).
Ownership category
akta.pro rank

NextMed industry classification

Industry
Product category
Urology Services
NAICS
Ambulatory Health Care Services (621)
SIC
Electromedical & Electrotherapeutic Apparatus (3845), Services-Health Services (8000)
akta.pro industry
PRIMARYHLAHAKAI
Kidney Stone Management & Lithotripsy Devices
SECONDARYHLACAGAA
Diagnostic & Triage Decision Support
Healthcare & Life Sciences/Digital Health & Health IT/Clinical Decision Support (CDS) & Care Pathway Tools
SECONDARYHLAKAOAF
Endourology & Minimally Invasive Urologic Surgery

Keywords

  • Mobile lithotripsy services
  • Kidney stone treatment
  • ESWL procedures
  • Urology practice support
  • AI treatment algorithms

Where NextMed is headquartered

Location

Headquarters

HQ city
Tucson
HQ country
United States
HQ region
North America

Offices1 record

Markets served

NextMed business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

  1. Lithotripsy Services: NextMed provides mobile lithotripsy services to urologists and medical facilities. The company operates mobile lithotripsy units that travel to partner facilities, providing non-invasive kidney stone treatment (ESWL). Physicians and facilities partner with NextMed to access state-of-the-art lithotripsy technology, highly trained technologists, and data-driven treatment protocols. The company was founded on principles of transparent financial operations.
  2. NextWave In-Office Treatment Services: NextWave brings kidney stone treatment directly to physician offices, providing in-office ESWL treatment with a focused treatment team. This service generates revenue by enabling physicians to perform lithotripsy in their own facilities with NextMed's equipment, technology, and technologist support.
  3. Physician Partnership Investments: Physicians invest in NextMed partnerships, with testimonials indicating significant returns. One physician noted a $50,000 total investment 15+ years ago netting a seven-figure return. This suggests a model where physicians become equity partners or investors in the lithotripsy business.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractCustom partnership pricing based on physician and facility needs
OtherMulti-year contractQuote-based pricing for lithotripsy services

Go-to-market motion3 records

Distribution channels4 records

Marketing channels8 records

NextMed product offering

Product offering

Core offering

NextMed provides mobile Extracorporeal Shock Wave Lithotripsy (ESWL) services to urologists and medical facilities across the United States, bringing lithotripsy equipment, AI-powered treatment protocols, and trained technologists directly to partner sites. The company also offers the NextWave in-office treatment service for physicians and the URS+ ureteroscopy program, all supported by the proprietary AI Smart Litho technology platform including the Stone Decision Engine and International Stone Registry.

Product overview

NextMed operates as a comprehensive urology services company offering a platform of lithotripsy and urological treatment services. The core offering consists of mobile lithotripsy services using ESWL technology, supplemented by the NextWave in-office treatment sub-brand and the URS+ ureteroscopy service. Central to their differentiation is the AI Smart Litho technology platform, which includes the Stone Decision Engine (predictive treatment recommendation tool), International Stone Registry (clinical outcomes database), and Hamilton, Gerber Training Simulator (physician training tool). NextMed delivers treatment through partnered physicians and facilities nationwide, serving over 400 facilities and 1,000 physicians with demonstrated outcomes including 99% patient success rate and 86.3% ESWL treatment success rate.

Differentiator

Problem solved

Functional benefit

Brands

  • NextWave: In-office kidney stone treatment service bringing ESWL treatment directly to physician offices, providing convenient in-office treatment options for patients.
  • URS+
  • AI Smart Litho

Products and services

  • Mobile Lithotripsy Service NextMed's core mobile lithotripsy service that deploys ESWL equipment and trained technologists to partner urology practices, hospitals, and medical facilities across the United States. Provides non-invasive kidney stone treatment on-site without requiring facilities to invest in lithotripsy equipment.
  • NextWave In-Office Treatment Sub-brand service that brings ESWL kidney stone treatment to the physician's office, allowing patients to receive treatment in their urologist's office rather than a hospital. Includes NextMed equipment, technologists, and focused treatment team support.
  • URS+ Ureteroscopy Service Comprehensive ureteroscopy service for urologists and medical facilities providing capital equipment, full suite of consumables, expert technicians, and flexible care settings to address labor shortages and capital equipment needs.
  • AI Smart Litho Technology Platform NextMed's proprietary AI technology platform integrating predictive algorithms, the Stone Decision Engine, the International Stone Registry, and the ESWL Training Simulator to optimize kidney stone treatment selection and delivery.
  • Stone Decision Engine (SDE) Standalone predictive tool for patients and physicians that determines the best kidney stone treatment options and predicts success and complication rates based on stone characteristics, patient demographics, and anesthesia preferences.
  • International Stone Registry (ISR) Clinical outcomes registry aggregating treatment and outcomes data from over 200,000 patients and 1,000 treating urologists, powered by cloud computing and advanced analytical tools to support treatment decisions.
  • Hamilton, Gerber ESWL Training Simulator ESWL training simulator for physicians that uses scientific data and patient-specific information to teach optimal shock protocol delivery for Extracorporeal Shock Wave Lithotripsy procedures.

Quantifiable outcome

  • 86.3% ESWL Treatment Success Rate in the last year with Stone Free Rate of 66.3%
  • +9 more outcomes

Companies that use NextMed

Customer profile

Named customers5 records

Segments4 records

Ideal customer profiles3 records

NextMed technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature6 records

NextMed partnerships and signals

Strategic signal

Scale indicators20 records

Recent moves6 records

Expansion highlights6 records

NextMed competitors and assessment

Company assessment

Broad incumbents

  • Karl Storz: Global leader in endoscopy and urology visualization systems. Karl Storz is a broad incumbent in urology whose ureteroscopy and endoscopy equipment overlaps with NextMed's URS+ ureteroscopy service line and broader urology practice economics.
  • Medtronic: Diversified medical device giant with a meaningful urology business (acquired through Covidien and other deals). Medtronic competes broadly in urology and is a potential alternative vendor for hospitals weighing mobile lithotripsy outsourcing versus in-house capital investment.
  • Cook Medical: Privately held medical device manufacturer with a substantial urology portfolio including ureteral stents, stone baskets, and ureteroscopy accessories. Cook Medical overlaps with NextMed's URS+ ureteroscopy consumables offering and broader urology supply chain.
  • Hologic: Diversified women's health and surgical company with adjacent urology and surgical service exposure. Hologic is a broad incumbent whose hospital relationships and surgical service infrastructure overlap with NextMed's facility-partnership go-to-market.
  • Teleflex: Medical technology company with a urology portfolio including ureteral access sheaths, stone baskets, and stents. Teleflex is an incumbent supplier whose products overlap with NextMed's URS+ consumables offering and broader urology procedure economics.
  • Boston Scientific: Large diversified medical device company with a significant urology franchise (including lithotripsy, ureteroscopy, and stone management products). Boston Scientific competes across multiple of NextMed's service lines as a broader incumbent.
  • Richard Wolf: German medical technology company specializing in urology, endoscopy, and lithotripsy solutions. Richard Wolf is a broad incumbent whose equipment and consumables portfolio competes across NextMed's mobile lithotripsy and ureteroscopy service lines.
  • Olympus: Global leader in endoscopy with strong urology exposure including flexible ureteroscopes and stone management devices. Olympus competes as an incumbent equipment vendor for hospitals and ASCs evaluating lithotripsy and ureteroscopy capabilities.

Direct peers

  • Storz Medical: Swiss manufacturer of shock wave lithotripsy and focused ultrasound devices. Storz Medical supplies ESWL equipment that competes with NextMed's mobile lithotripsy service offering and is a likely technology partner or competitor for any hospital considering insourcing.
  • Dornier MedTech: A leading global manufacturer of lithotripsy devices and ESWL systems. Dornier competes directly with NextMed in the kidney stone management equipment market that NextMed services, particularly for hospitals evaluating whether to outsource mobile lithotripsy or purchase equipment.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

NextMed social profiles

Digital presence

NextMed compliance and trust

Trust signal

Compliance3 records

NextMed financial estimates

Financial estimate

Revenue estimate

Valuation estimate

NextMed leadership team

Management profile

Number of profiles

Profiles2 records

NextMed funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

NextMed M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about NextMed

What does NextMed do?

NextMed provides mobile Extracorporeal Shock Wave Lithotripsy (ESWL) services to urologists and medical facilities across the United States, bringing lithotripsy equipment, AI-powered treatment protocols, and trained technologists directly to partner sites. The company also offers the NextWave in-office treatment service for physicians and the URS+ ureteroscopy program, all supported by the proprietary AI Smart Litho technology platform including the Stone Decision Engine and International Stone Registry.

Is NextMed a public or private company?

NextMed is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was NextMed founded?

NextMed was founded in 1996. It employs 101 to 250 people.

Where is NextMed based?

NextMed is headquartered in Tucson, United States, in the North America region.

How does NextMed make money?

Three revenue lines are on record. Lithotripsy Services are the primary driver. The others are nextWave In-Office Treatment Services and physician Partnership Investments.

Who are NextMed's main competitors?

Broad incumbents on record are Karl Storz, Medtronic, Cook Medical, Hologic, Teleflex, Boston Scientific, Richard Wolf and Olympus. Direct peers are Storz Medical and Dornier MedTech.

Does NextMed have an API?

No public API is recorded for NextMed.

What industry is NextMed in?

NextMed's product category is Urology Services. Its primary akta.pro industry code is HLAHAKAI, Kidney Stone Management & Lithotripsy Devices, with a secondary code of HLACAGAA, Diagnostic & Triage Decision Support. Its NAICS code is 621 and its SIC code is 3845.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals